隶属于 touro college & university system
相关临床试验
71
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1860
进行中（未招募）
4
5.6%
已完成
22
31.0%
尚未招募
4
5.6%
招募中
20
28.2%
终止
8
11.3%
Unknown
10
14.1%
撤回
3
4.2%
暂无批准数据
- The ESPRESSo trial found that high-intensity therapy starting within two weeks of stroke did not improve hand and arm recovery beyond standard care, challenging the "more therapy, earlier" approach. - Sixty-four stroke survivors received an extra 90 minutes of daily therapy for three weeks, but showed identical three-month outcomes to patients receiving standard care alone. - The study suggests early stroke recovery is dominated by natural biological repair processes that cannot be enhanced by increasing therapy dose above standard care. - Results indicate that intensive therapy may be more effective later in recovery when patients can engage more fully, rather than during the acute phase.
- Real-world data from nearly 40,000 patients reveals aflibercept 8 mg allows for extended dosing intervals of 2+ weeks in neovascular AMD patients compared to previous anti-VEGF treatments. - Treatment-experienced patients switching to aflibercept 8 mg demonstrated dosing interval extensions of 16-21 days, with treatment-naive patients achieving approximately 10-week intervals between injections. - Early efficacy data shows vision improvements in patients with baseline vision of 20/50 or worse, suggesting potential benefits in both treatment-naive and treatment-experienced populations.
- National Health Interview Survey analysis shows 45.2% of parents with children having atopic dermatitis fail to get recommended 7 hours of sleep, compared to 37.1% of other parents. - Parents of children with eczema are 26% more likely to use sleep medications, with 13.3% reporting sleep aid use versus 9.9% in the control group. - The study, analyzing data from 2013-2018, represents over 6.1 million U.S. parents, highlighting the significant indirect health impact of pediatric atopic dermatitis on caregivers.
